US OptionsDetailed Quotes
BMY241220C57500
- 0.18
- -0.13-41.94%
15min DelayClose Dec 13 16:00 ET
0.34High0.14Low
0.22Open0.31Pre Close200 Volume8.41K Open Interest57.50Strike Price4.04KTurnover31.96%IV3.41%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier4DDays to Expiry0.18Extrinsic Value100Contract SizeAmericanOptions Type0.2010Delta0.1443Gamma259.44Leverage Ratio-0.0647Theta0.0013Rho52.14Eff Leverage0.0171Vega
Bristol-Myers Squibb Stock Discussion
Sign in to post a comment
$Esperion Therapeutics (ESPR.US)$ Acquiring Esperion Therapeutics could be a strategic move for a big pharmaceutical company for several compelling reasons. Here are the main factors that suggest an acquisition could be beneficial for a larger player in the pharmaceutical industry:
1. Unique Market Position in Statin Alternatives
– Addressing Statin Intolerance: There are millions of statin...
1. Unique Market Position in Statin Alternatives
– Addressing Statin Intolerance: There are millions of statin...
6
1
1
Buckle up! See FDA PDUFA update 👇
$Ionis Pharmaceuticals (IONS.US)$ ⇨ IONIS-APOCIII-LRx (Olezarsen)
$ZLDPF ⇨ Glepaglutide
$Rhythm Pharmaceuticals (RYTM.US)$ ⇨ IMCIVREE™ (Setmelanotide)
$Mirum Pharmaceuticals (MIRM.US)$ ⇨ Chenodal® (chenodiol)
$Checkpoint Therapeutics (CKPT.US)$ ⇨ Cosibelimab (CK-301)
$Neurocrine Biosciences (NBIX.US)$ ⇨ Crinecerfont capsule
$Bristol-Myers Squibb (BMY.US)$ ⇨ Opdivo® Subcutaneous (nivolumab + hyaluronidase)
$Neurocrine Biosciences (NBIX.US)$ ⇨ Crinecerfont oral solution
$BeiGene (BGNE.US)$ ⇨ Tisleli...
$Ionis Pharmaceuticals (IONS.US)$ ⇨ IONIS-APOCIII-LRx (Olezarsen)
$ZLDPF ⇨ Glepaglutide
$Rhythm Pharmaceuticals (RYTM.US)$ ⇨ IMCIVREE™ (Setmelanotide)
$Mirum Pharmaceuticals (MIRM.US)$ ⇨ Chenodal® (chenodiol)
$Checkpoint Therapeutics (CKPT.US)$ ⇨ Cosibelimab (CK-301)
$Neurocrine Biosciences (NBIX.US)$ ⇨ Crinecerfont capsule
$Bristol-Myers Squibb (BMY.US)$ ⇨ Opdivo® Subcutaneous (nivolumab + hyaluronidase)
$Neurocrine Biosciences (NBIX.US)$ ⇨ Crinecerfont oral solution
$BeiGene (BGNE.US)$ ⇨ Tisleli...
6
1
Buckle up! See FDA PDUFA update 👇🧵
$Ionis Pharmaceuticals (IONS.US)$ ⇨ IONIS-APOCIII-LRx (Olezarsen)
$ZLDPF ⇨ Glepaglutide
$Rhythm Pharmaceuticals (RYTM.US)$ ⇨ IMCIVREE™ (Setmelanotide)
$Mirum Pharmaceuticals (MIRM.US)$ ⇨ Chenodal® (chenodiol)
$Checkpoint Therapeutics (CKPT.US)$ ⇨ Cosibelimab (CK-301)
$Neurocrine Biosciences (NBIX.US)$ ⇨ Crinecerfont capsule
$Bristol-Myers Squibb (BMY.US)$ ⇨ Opdivo® Subcutaneous (nivolumab + hyaluronidase)
$Neurocrine Biosciences (NBIX.US)$ ⇨ Crinece...
$Ionis Pharmaceuticals (IONS.US)$ ⇨ IONIS-APOCIII-LRx (Olezarsen)
$ZLDPF ⇨ Glepaglutide
$Rhythm Pharmaceuticals (RYTM.US)$ ⇨ IMCIVREE™ (Setmelanotide)
$Mirum Pharmaceuticals (MIRM.US)$ ⇨ Chenodal® (chenodiol)
$Checkpoint Therapeutics (CKPT.US)$ ⇨ Cosibelimab (CK-301)
$Neurocrine Biosciences (NBIX.US)$ ⇨ Crinecerfont capsule
$Bristol-Myers Squibb (BMY.US)$ ⇨ Opdivo® Subcutaneous (nivolumab + hyaluronidase)
$Neurocrine Biosciences (NBIX.US)$ ⇨ Crinece...
4
Happy Monday, November 11th. The market climbed to a trifecta of closing highs for indices. The S&P 500 broke through 6k Friday and traded above the historic mark again Monday before the market pulled back in the afternoon.
Just past 4 pm ET the $S&P 500 Index (.SPX.US)$ traded +10 bps, the $Dow Jones Industrial Average (.DJI.US)$ climbed 69 bps, and the $Nasdaq Composite Index (.IXIC.US)$ climbed 0.06%.
MACRO
In macroecon...
Just past 4 pm ET the $S&P 500 Index (.SPX.US)$ traded +10 bps, the $Dow Jones Industrial Average (.DJI.US)$ climbed 69 bps, and the $Nasdaq Composite Index (.IXIC.US)$ climbed 0.06%.
MACRO
In macroecon...
44
12
9
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Good morning, traders. Happy Monday, November 11th. The market is climbing, but some tech firms are pulling back after hitting post-election records. The S&P 500 broke through 6,000 Friday and traded above the historic mark again Monday.
My name is Kevin Travers; here is the news and animal spirits moving markets today.
$Monolithic Power Systems (MPWR.US)$ shares fell 22%, the lowest decliner on the S&P 500 and Nasdaq, after a report from analysts at Edgew...
My name is Kevin Travers; here is the news and animal spirits moving markets today.
$Monolithic Power Systems (MPWR.US)$ shares fell 22%, the lowest decliner on the S&P 500 and Nasdaq, after a report from analysts at Edgew...
44
5
6
Portfolio diversification is the strategy of spreading investments across different assets, sectors, industries, and geographical regions to reduce the overall risk of the portfolio. The idea is that by holding a variety of investments, the overall performance of the portfolio will be less dependent on the performance of any single investment, reducing the risk of large losses.
Why is Portfolio Diversification Important?
1. Risk Reduction:
Diversification...
Why is Portfolio Diversification Important?
1. Risk Reduction:
Diversification...
36
1
34
Stocks to Watch
Abbott Laboratories (ABT US) $Abbott Laboratories (ABT.US)$
Daily Chart -[BULLISH ↗ **]ABT US is currently holding above short term ascending trendline support. As long as price is holding above 117.30 support, a further push higher towards 1st resistance at 123.80 then next resistance at 131.20 is expected. Technical indicators are advocating for a bullish scenario as well.
Altern...
Abbott Laboratories (ABT US) $Abbott Laboratories (ABT.US)$
Daily Chart -[BULLISH ↗ **]ABT US is currently holding above short term ascending trendline support. As long as price is holding above 117.30 support, a further push higher towards 1st resistance at 123.80 then next resistance at 131.20 is expected. Technical indicators are advocating for a bullish scenario as well.
Altern...
+3
31
4
2
See FDA PDUFA update 👀 👇
📌 This Week’s PDUFA:
$ZLDPF: 🤔
‣ Dasiglucagon
‣ Congenital Hyperinsulinism
‣ PDUFA: 10/08/24
📣 Last Week’s PDUFA decisions:
$Biofrontera (BFRI.US)$ : Approved ✅
⇨ Ameluz
‣ Actinic keratosis
‣ PDUFA: 10/04/24 (sNDA)
$Bristol-Myers Squibb (BMY.US)$ : Approved ✅
⇨ Neoadjuvant Opdivo (nivolumab) + Chemo
‣ NSCLC (perioperative treatment)
‣ PDUFA: 10/08/24
📌 This Week’s PDUFA:
$ZLDPF: 🤔
‣ Dasiglucagon
‣ Congenital Hyperinsulinism
‣ PDUFA: 10/08/24
📣 Last Week’s PDUFA decisions:
$Biofrontera (BFRI.US)$ : Approved ✅
⇨ Ameluz
‣ Actinic keratosis
‣ PDUFA: 10/04/24 (sNDA)
$Bristol-Myers Squibb (BMY.US)$ : Approved ✅
⇨ Neoadjuvant Opdivo (nivolumab) + Chemo
‣ NSCLC (perioperative treatment)
‣ PDUFA: 10/08/24
4
1
2
$Bristol-Myers Squibb (BMY.US)$ what a convenient dip before the 500 day on the weekly for people to accumulate before the big news.. now back to it and omg.. guess what time it is.. Big Pharm Bull Run time.. yay.. just a beautiful timed pullback.. nothing to see here.. oh and earnings on October 31st with some others cant forget that.. dividends too.. oh it just never ends
2
No comment yet
Alwayslearning5 : LOL